All In Biotech

Investigational drug · Phase 2

INO-9012

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HCC, Glioblastoma, Urothelial Carcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

4

3 still active

All registered trials

16

Any phase or sponsor naming "INO-9012"

First trial start

2018

May 31, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "INO-9012", any sponsor or status.

Conditions studied

As listed on its trial records.

  • HCC
  • Glioblastoma
  • Urothelial Carcinoma

Approved drugs for the same conditions: Bladder and urothelial cancer · Brain tumors (glioma) · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "INO-9012" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for HCC

  • ApatinibRIVO, RivoceranibPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • VRT106Phase 33 trials

    Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC

  • tirapazaminePhase 32 trials

    Zhejiang Raygene Pharmaceuticals Co., Ltd · HCC, Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic

  • GNOS-PV02Phase 22 trials

    Geneos Therapeutics · HCC

  • FOG-001Phase 21 trial

    Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor

  • PM1009Phase 21 trial

    Biotheus Inc. · HCC, Liver Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.